Engineered proteins form the basis of biologic medicines, yet most candidates fail during development. MIT Tech Review highlights how AI tools now predict protein folding and binding more accurately. This reduces the cost of early-stage discovery. Researchers can now bypass years of trial-and-error lab work to identify viable drug candidates faster.